Share This Link

Memory fragmentation is a hallmark symptom of DID and contributes to the client’s distress and functional impairment. However, while important for diagnosis and treatment planning, it does not supersede safety concerns such as self-harm risk.

Cognitive function may be affected in DID, especially during dissociative episodes, but it is not typically the most urgent concern unless it directly compromises safety or decision-making capacity.

Self-esteem issues are common in DID and may influence therapeutic engagement and long-term recovery. However, they are not considered an immediate priority compared to assessing for self-harm risk.

While understanding defense mechanisms can help guide long-term therapeutic strategies, it is not the immediate priority during initial assessment. Defense mechanisms are often unconscious and may not be readily observable or relevant to acute care.

Administering medications may be necessary, but pharmacologic intervention should follow a thorough assessment. Giving medications without understanding the severity or triggers of anxiety could mask symptoms or lead to inappropriate treatment.

Limiting environmental stimuli may help reduce anxiety, but it is an intervention that should be tailored based on the assessment findings. Without first evaluating the patient’s anxiety level, this action may be insufficient or misdirected.

This question is more relevant to assessing for post-traumatic stress disorder (PTSD) or acute stress reactions, not generalized anxiety disorder (GAD).

Repetitive behaviors suggest obsessive-compulsive disorder (OCD), not GAD. While anxiety may be present in both, the symptom profile differs significantly.

Discomfort in social situations is more indicative of social anxiety disorder. GAD involves pervasive worry across multiple domains, not just social interactions.

This reflects generalized anxiety and does not indicate dissociative symptoms.

Feeling like living in a dream state suggests depersonalization or derealization, which are dissociative symptoms but not specific to fugue.

This statement is more aligned with dissociative identity disorder (DID), where internal conflict between identities is common.

Weight gain is not a typical symptom of post-traumatic stress disorder (PTSD) or acute stress response. It may occur due to other factors but is not directly linked to trauma.

Headaches may occur after trauma, especially if there was physical injury or stress, but they are not as specific or diagnostic as flashbacks in this context.

Weight gain is not a typical direct symptom of trauma-related disorders such as PTSD. While changes in appetite and weight can occur in depression or anxiety, they are not hallmark signs of post-traumatic stress.

Headaches may occur due to stress or anxiety, but they are nonspecific and not diagnostic of trauma-related disorders. They lack the psychological re-experiencing component that flashbacks provide.

Increased appetite may be seen in some mood disorders but is not a primary or expected finding in trauma-related assessments. It does not reflect the psychological impact of the event.

While reassurance may provide temporary comfort, it lacks the educational component necessary for informed consent and understanding of pharmacodynamics. It may also come off as dismissive if not paired with factual information.

Increasing the dose at day 5 is premature and not evidence-based. Dose adjustments should only be considered after an adequate trial period, typically several weeks, unless adverse effects or worsening symptoms occur.

Assessing for improvement is part of ongoing care, but at day 5, significant symptom relief is unlikely. The priority is to educate the client about the expected timeline rather than prematurely evaluate efficacy.

While understanding defense mechanisms can help in long-term psychological care, it is not the immediate priority during initial assessment. It requires deeper therapeutic engagement and is secondary to evaluating current distress.

Administering medications may be necessary, but pharmacologic intervention should follow a thorough assessment. Giving medication without understanding the severity or triggers of anxiety can be inappropriate or unsafe.

Reducing stimuli can help manage anxiety, but it is an intervention that should be tailored based on the assessment. Without knowing the patient’s current anxiety level, this action may not be sufficient or appropriate.

Reassurance alone does not provide the necessary information for the client to understand their treatment plan. It may be perceived as dismissive if not accompanied by education.

Dose changes should not be considered this early unless there are adverse effects or clinical deterioration. The standard protocol is to wait several weeks before evaluating the need for adjustment.

While monitoring for improvement is part of ongoing care, it is not the priority at day 5. The nurse should first ensure the client understands the expected timeline for symptom relief.

Acamprosate calcium is used to maintain abstinence in alcohol-dependent individuals by modulating glutamatergic neurotransmission. It does not induce aversive effects and is not part of aversion therapy.

Naltrexone is an opioid antagonist that reduces cravings and the rewarding effects of alcohol and opioids. It is not aversive in nature and does not cause unpleasant reactions upon substance use.

Quetiapine fumarate is an atypical antipsychotic used for mood disorders and schizophrenia. It has no role in aversion therapy or addiction treatment through negative conditioning.